Physiomics PLC IMC Presentation on Board Changes

RNS Number : 2609I

Physiomics PLC

15 October 2024

 

15 October 2024

 

Physiomics plc

("Physiomics" or the "Company")

 

IMC Presentation on Company Website

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its End of Year results via Investor Meet Company and has updated its website with the presentation.

 

The presentation and Q&A from the meeting are now available at the Company's website:

https://www.physiomics.co.uk/portfolio-item/investor-presentation-full-year-results-and-company-update/

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, Non-Executive Chairman

Dr Peter Sargent, Chief Executive Officer

[phone]

 

Hybridan LLP (Broker)

Claire Louise Noyce

[phone]

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

[phone]

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAGZMMGGKDGDZM